Caribou Biosciences (NASDAQ: CRBU) — Perfil da empresa, notícias e dados financeiros
Caribou Biosciences focuses on CRISPR technology for innovative therapeutic treatments addressing unmet medical needs.
Caribou Biosciences
Caribou Biosciences (NASDAQ:CRBU) is a biotechnology company focused on revolutionizing healthcare through the development of CRISPR-based technology platforms for genome editing. With a strong commitment to innovation, Caribou is actively pursuing a diverse range of projects aimed at developing therapeutic treatments that can address unmet medical needs across various diseases. The company is at the forefront of utilizing CRISPR-Cas systems to engineer cell therapies with the potential to deliver life-changing benefits to patients. As part of its objectives, Caribou is dedicated to advancing its pipeline of products through rigorous scientific research, while upholding the highest standards of quality and ethical considerations in gene editing.
Resumo
Operações
Produtos e/ou serviços de Caribou Biosciences
- CRISPR-Cas genome editing technology for developing advanced cell therapies.
- Allogeneic CAR-T cell therapies targeting hematologic cancers.
- CB-010, the lead allogeneic CAR-T cell therapy for B cell malignancies.
- In vivo gene editing programs for various genetic diseases.
- Next-generation CRISPR technologies for enhanced precision and efficiency.
- Collaborations with pharmaceutical companies to utilize CRISPR for drug discovery and development.
equipe executiva do Caribou Biosciences
- Rachel E. HaurwitzCo-Founder, CEO, President & Director
- Sriram RyaliChief Financial Officer
- Barbara G. McClungChief Legal Officer & Corporate Secretary
- Jennifer A. DoudnaCo-founder & Member of Scientific Advisory Board
- Ryan FischesserInterim Principal Accounting Officer & Controller
- Justin SkobleSenior Vice President of Technical Operations
- Reigin ZawadzkiChief People Officer
- Tina AlbertsonChief Medical Officer
- Enrique ZudaireSenior Vice President of Translational Research
Comunicados recentes
O que a Caribou Biosciences (CRBU) comunicou ao mercado, do mais recente para o mais antigo.
- NEWS_HALT halt | CRBUFato relevante
Principais indicadores financeiros
Resultados divulgados pela Caribou Biosciences, em USD.
- Cap. de mercado
- 52,5 mi
- Receita (TTM)
- 10 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 11,2 mi | -136,2 mi | -148,1 mi | |
| 10 mi | -166,6 mi | -149,1 mi | |
| 34,5 mi | -116,1 mi | -102,1 mi | |
| 13,9 mi | -106,4 mi | -99,4 mi |